Poster on Binge-Eating Model Selected as SFN 'Hot Topic'


RenaSci's scientific communication on the efficacy of lisdexamfetamine in a rodent model of binge-eating disorder was one of only 200 'Hot Topics' selected out of more than 15,000 abstracts by the Society for Neuroscience at last months Annual Meeting in San Diego, California, USA. The meeting was attended by more than 30,000 delegates from across the world. For further information on our rat model of binge-eating disorder please click here

RenaSci Expert Speaks at European Launch of Lilly's Strattera (Atomoxetine) for the Treatment of Adults with ADHD


One of our Directors, Professor David Heal, was an invited speaker at the European launch of Lilly's Strattera (atomoxetine) for the treatment of adults diagnosed with attention deficit hyperactivity disorder (ADHD). The Adult ADHD Launch Meeting 'Changing paradigms in the treatment of ADHD: Adults are important too' was on 25th to 27th September 2013 in the London Hilton Metropole, London, UK. The conference was chaired by Professor David Nutt (UK) and Professor István Bitter (Hungary). David gave a talk entitled 'The pharmacology of medications used in ADHD' that described the pharmacological mechanisms underlying the efficacy and potential side-effects of the different drugs currently used to treat ADHD and also discussed what the future may hold for the pharmacological treatment of this disorder.



RenaSci has recently acquired a Lunar PIXImus Densitomer and now offers bone and tissue composition analysis in mice by dual-energy X-ray absorptiometry (DEXA). We have validated the DEXA technology by demonstrating excellent correlation between the fat content of dietary-induced obese mice determined by DEXA with results obtained using gold standard chemical extraction techniques. Measures provided by DEXA include fat mass (%), fat mass (g), total tissue mass (g), lean mass (g), bone mineral density (g/cm2) and bone mineral content (g). The main advantage of DEXA is that it can be performed in live animals. This means that we can now provide longitudinal measurements of tissue and bone composition throughout chronic mouse studies. Furthermore, data is provided within 5 min, therefore DEXA is much quicker and cheaper than conventional body composition analysis. For further information about DEXA please click here

RenaSci Awarded CIR Accreditation


We are pleased to announce that we have recently acquired Research Tax Credit (Crédit d'Impôt Recherche, CIR) accreditation from the French Ministry of Higher Eduaction and Research. This powerful tax incentive is offered by the French Government to encourage science and innovation in France. The tax credit covers 30% of all R&D expenses up to €100 million, and 5% above this threshold. It includes subcontracted research activities. The recognition of RenaSci as an eligible CRO for French Research Tax Credit by the French Government means that companies located in France will now be able to claim substantial tax credits on R&D activities outsourced to us. Please contact us for further information or if you would like to see a copy of the letter granting RenaSci French Research Tax Credit accreditation.

Cobas c 111 Analyser


We have recently installed a fully-automated Cobas c 111 clinical chemistry analyser. The Cobas analyser will give us access to the Roche clinical reagent range and will therefore expand the range of assays that we can perrform on samples of serum, plasma, whole blood and urine from our animal models of diabetes and obesity. For further information please click here